InMode Ltd. (INMD) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: improved EPS and cash flow management are positive, but decreased annual EPS and lower margins due to new product costs and tariffs are concerning. The Q&A highlights slight market improvements and strategic alternatives, yet uncertainties remain about new product revenue and international growth. The market cap indicates moderate sensitivity to news, and the lack of strong guidance adjustments tempers expectations. Overall, the neutral sentiment reflects balanced positive and negative factors, leading to a predicted stock movement within -2% to 2%.
Key Financial Performance
Total Revenue (Q4 2025) $103.9 million, up from $97.9 million in Q4 2024, representing an increase. The increase was attributed to strong performance in international operations, particularly in Europe.
Total Revenue (Full Year 2025) $370.5 million, a 6% decrease compared to 2024. The decline was due to ongoing challenges in the aesthetic industry, including higher interest rates and softer customer demand.
Revenue from Sales Outside the U.S. (Q4 2025) $48.5 million, representing 47% of total sales and a 38% increase compared to Q4 2024. The growth was primarily driven by strong performance in Europe.
Revenue from Sales Outside the U.S. (Full Year 2025) $171.8 million, accounting for 46% of total sales and a 15% increase compared to 2024. The increase was driven by momentum in international markets, especially Europe.
Gross Margins (Q4 2025) 78% on a GAAP basis, compared to 79% in Q4 2024. The slight decrease was due to changes in the product mix.
Gross Margins (Full Year 2025) 79% on a non-GAAP basis, consistent with the previous year.
Revenue from Minimally Invasive Technology Platforms (Q4 2025) 76% of total revenues. This reflects the company's focus on minimally invasive solutions.
Revenue from Minimally Invasive Technology Platforms (Full Year 2025) 78% of total revenues, indicating a strong contribution from these platforms.
Revenue from Consumables and Services (Full Year 2025) 22% of total revenue, up from 20% in 2024. The increase suggests higher usage levels across the installed base.
GAAP Operating Expenses (Q4 2025) $55.3 million, an 11% increase year-over-year. The rise was due to higher sales and marketing expenses.
GAAP Operating Expenses (Full Year 2025) $205.6 million, a 0.5% increase compared to 2024. The slight increase was driven by higher salaries and employee-related expenses.
Non-GAAP Operating Expenses (Q4 2025) $53.2 million, a 13.5% increase compared to Q4 2024. The increase was attributed to higher sales and marketing expenses.
Non-GAAP Operating Expenses (Full Year 2025) $195.8 million, up from $189.8 million in 2024. The increase was due to higher operational costs.
GAAP Operating Margin (Q4 2025) 25%, compared to 32% in Q4 2024. The decline was primarily due to higher sales and marketing expenses.
GAAP Operating Margin (Full Year 2025) 23%, down from 33% in 2024. The decrease was attributed to increased operational costs.
Non-GAAP Operating Margin (Q4 2025) 27%, compared to 32% in Q4 2024. The decline was due to higher sales and marketing expenses.
Non-GAAP Operating Margin (Full Year 2025) 26%, down from 33% in 2024. The decrease was due to increased operational costs.
GAAP Diluted Earnings Per Share (Q4 2025) $0.42, compared to $1.14 in Q4 2024. The significant decrease was due to a one-time tax benefit in 2024.
GAAP Diluted Earnings Per Share (Full Year 2025) $1.43, compared to $2.25 in 2024. The decline was due to reduced sales and higher operational costs.
Non-GAAP Diluted Earnings Per Share (Q4 2025) $0.46, compared to $0.42 in Q4 2024. The increase reflects improved operational efficiency.
Non-GAAP Diluted Earnings Per Share (Full Year 2025) $1.60, compared to $1.76 in 2024. The decrease was due to reduced sales and higher operational costs.
Cash and Cash Equivalents (End of 2025) $555.3 million. The company returned $127.4 million to shareholders through a share repurchase program.
Cash Generated from Operating Activities (Q4 2025) $22.7 million, reflecting strong cash flow management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CO2 laser platforms: Launched in 2025, performing well and expanding the portfolio by enabling combined treatments.
Upcoming platforms: Plan to introduce two new platforms in 2026: a Korean-made pico laser device and a device combining Morpheus technology with Erbium:YAG laser.
Product mix: Most offerings include Morpheus8 or minimally invasive components, reflecting a comprehensive solution portfolio.
North American business restructuring: Unified operations across Eastern U.S., Western U.S., and Canada under new leadership, expected to deliver results in 2026.
International operations: Record revenue in Europe in Q4 2025, with sales outside the U.S. increasing by 38% in Q4 and 15% for the full year compared to 2024.
Sales team segmentation: Sales force segmented into aesthetic and wellness categories, with specialized teams for specific platforms.
Financial performance: Total revenue for 2025 was $370.5 million, a 6% decrease from 2024. Consumables and services revenue increased to 22% of total revenue, up from 20% in 2024.
Innovation strategy: Commitment to launching two new platforms annually to enhance value proposition and maintain leadership in the aesthetic industry.
Stabilization focus: 2026 viewed as a stabilization year following industry softness, with early signs of recovery in the U.S. and Europe.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Higher interest rates and softer customer demand: The aesthetic industry is facing challenges due to higher interest rates and reduced customer demand, which could impact InMode's revenue and market performance.
Decline in total revenue: Total revenue declined approximately 6% year-over-year, indicating potential financial challenges and market softness.
Economic slowdown and demand in North America: The global economic slowdown has not fully recovered, and demand in North America remains below historical levels, posing risks to revenue growth.
Leadership and structural changes in North America: The impact of leadership changes and structural reorganization in North America is yet to be realized, creating uncertainty about their effectiveness in driving results.
Increased operating expenses: Operating expenses, particularly in sales and marketing, have increased, which could pressure profit margins.
Decreased operating margins: Non-GAAP operating margins decreased from 33% in 2024 to 26% in 2025, reflecting financial pressures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue expectations: Revenues for 2026 are expected to be between $365 million to $375 million, broadly in line with 2025.
Product launches: Two new platforms are planned for launch in 2026: a Korean-made pico laser device and a device combining the new Morpheus technology with Erbium:YAG laser.
Market trends: The industry has not yet fully recovered from the global economic slowdown. Demand in North America remains below historical levels, but there are early signs of stabilization in the U.S. and gradual improvement in Europe.
Financial projections: Non-GAAP gross margin is expected to be between 75% and 77%. Non-GAAP income from operations is projected to be between $87 million and $92 million. Non-GAAP earnings per diluted share are anticipated to range from $1.43 to $1.48.
Strategic focus: The company plans to continue disciplined execution of its product roadmap, refine its sales team, and maintain its leadership position in the aesthetic industry.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: InMode returned $127.4 million back to the shareholders through a disciplined share repurchase program in 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What signs suggest improving trends in the market?
A:Interest rates have started to come down, which is beneficial for leasing packages used by doctors to purchase capital equipment. There is also a slight increase in the number of procedures and sales of consumables, as well as a slight revenue increase in Europe. These are early signs of potential positive momentum.
Q:What can you share about the process and timing of strategic alternatives?
A:The Board of Directors is considering several strategic alternatives to improve the company's value, which they believe is still low. They have hired Bank of America to assist in this process. Management is not fully involved in this process. Regarding Steel Partners' press release about buying 51% of the company, there has been no contact or discussion with them.
Q:Why did the gross margin and EBIT margin guidance come in lower?
A:The company is launching new laser products, which tend to have lower gross margins. Additionally, some products are being sourced externally, which increases costs. U.S. tariffs on imports from Israel also impact gross margins, which are expected to be around 75%.
Q:How much does the laser market contribute to the company's growth?
A:The laser market is a saturated market with relatively low prices and margins. However, the company believes that combining laser technology with their RF technology will create a competitive advantage. The laser market is essential for long-term growth.
Q:What is the financial contribution of the two new product launches in 2025?
A:The two new products launched in 2025, Solaria (CO2) and ApexRF, contributed approximately $15 million in revenue.
Q:What are the plans for new product launches in 2026?
A:In 2026, the company plans to launch a new Morpheus platform combined with Erbium:YAG technology and a pico laser sourced from a Korean company. These products are expected to be well-received, but no specific revenue estimates were provided.
Q:What caused the decline in minimally invasive procedures in 2025?
A:Minimally invasive procedures are more expensive than noninvasive ones, and consumers with limited budgets tend to opt for less expensive treatments. Additionally, the number of procedures did not grow significantly despite an increase in system placements. The use of GLP-1 for fat loss also impacted demand for minimally invasive procedures.
Q:What is the company's approach to expanding into new countries?
A:The company has expanded into smaller countries like Austria, Belgium, Scotland, and Ireland through existing subsidiaries. They also established new subsidiaries in Argentina and Thailand, replacing underperforming distributors. Direct sales now account for 80% of revenue.
Q:What are the expectations for R&D and marketing spend in 2026?
A:R&D spending will increase due to two large clinical studies for women's health, costing $2-4 million each. Marketing spending will remain focused but similar in percentage to 2025, with efforts on B2B, B2C, social media, and conferences.
Q:What is the update on the clinical work for the dry eye indication?
A:The company is working on obtaining FDA approval for a dry eye indication using bipolar RF technology. The study is expected to last through 2026 and into early 2027, with final clearance anticipated in the second quarter of 2027.
Q:What is the company's capital allocation strategy for 2026?
A:The Board is evaluating all capital allocation alternatives alongside strategic alternatives. Updates will be shared when available.
Q:What is the performance of the Apex men's wellness platform?
A:The Apex platform is being sold by the existing sales team and not a specialized team. The company is not heavily promoting it yet due to pending FDA indications.
Q:How many consumable units were sold in the quarter?
A:228,000 consumable units were sold in the quarter.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue estimates for the new product launches in 2026, citing uncertainty. They also did not provide a clear answer on whether international revenue would surpass North American revenue in 2026. Additionally, they did not elaborate on the capital allocation strategy, stating that the Board is still evaluating options.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America level
CO laser
Canada timing
Demand North
Eastern Western
Erbium YAG
Europe momentum
Europe sale
Europe support
Full Conference
InMode Full
InMode conference
InMode position
Korean pico
Morpheus technology
Non margin
Non technology
Product pillar
Revenues margin
Western Canada
base
component
consumables service
customer
decrease sale
device
margin Non
outcome
patient
product mix
share compensation
sign stabilization
solution
technology platform
INMD Transcript
InMode Ltd. (INMD) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call reveals strong financial performance with a 20% revenue increase and stable gross margins, indicating effective cost management. Operating and net income both showed significant growth, supported by robust cash flow. Despite the lack of strategic insights or detailed guidance, the positive financial metrics suggest a favorable outlook. The market cap suggests moderate volatility, so a positive sentiment is likely, but not strong enough for a substantial surge.
Peyto Exploration & Development Corp. (PEY:CA) Q4 2025 Earnings Call Transcript
Positive3-11
The earnings call highlights strong financial performance, with record quarterly earnings, increased production, and reduced costs. The company's strategic initiatives, such as exploring third-party processing and M&A opportunities, demonstrate proactive market positioning. Despite some management evasiveness in the Q&A, overall sentiment is positive due to strong financial metrics, optimistic guidance, and shareholder returns. The market cap suggests a moderate reaction, leading to a positive prediction for stock movement.
InMode Ltd. (INMD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
InMode Ltd. (INMD) Q4 2025 Earnings Call Transcript
Unknown2-10
The earnings call reveals mixed signals: improved EPS and cash flow management are positive, but decreased annual EPS and lower margins due to new product costs and tariffs are concerning. The Q&A highlights slight market improvements and strategic alternatives, yet uncertainties remain about new product revenue and international growth. The market cap indicates moderate sensitivity to news, and the lack of strong guidance adjustments tempers expectations. Overall, the neutral sentiment reflects balanced positive and negative factors, leading to a predicted stock movement within -2% to 2%.
INMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
